The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 7.85% ...

By studying the effects of the nasal anti-CD3 in a ... Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

In recently published research in the journal Neurology, the team tracked records for 4,593 people living with multiple sclerosis from 2019 to 2020, 673 in rural areas and 3,920 in urban centers.

Get Instant Summarized Text (Gist) New therapeutic targets for multiple sclerosis (MS) tissue recovery have been identified, potentially leading to treatments that promote myelin repair. Current ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or untreated. A machine learning model may help by analyzing routinely collected ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study suggests that supplementing it in high doses could help reduce symptoms.

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial ...

Bike MS hosts its MS 150 bike ride over the weekend to bring awareness and funds towards curing Multiple Sclerosis (MS). This 150-mile bike ride is not a race, but rather a fundraiser across the ...

More data are needed on its efficacy and safety in treating relapsing multiple sclerosis. In two phase 3, double-blind, double-dummy, event-driven trials (GEMINI 1 and GEMINI 2), participants with ...